Matinas BioPharma Holdings (MTNB) Other Working Capital Changes (2014 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Other Working Capital Changes of -$165000.0 for Q1 2026, up 7.82% year-over-year from -$153031.1 in Q1 2025, and up 65.91% quarter-over-quarter from -$484000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Other Working Capital Changes (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Other Working Capital Changes for 6 consecutive years, with -$165000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 7.82% year-over-year to -$165000.0; the TTM figure through Mar 2026 stood at -$1.0 million (down 51.18% YoY), while the FY2025 annual figure was -$1.0 million, down 59.08% from the prior year.
- Other Working Capital Changes rose to -$165000.0 in Q1 2026 per MTNB's latest filing, from -$484000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $2.2 million in Q2 2022 and bottomed at -$2.4 million in Q1 2023.
- Historically, Other Working Capital Changes has averaged -$41000.0 across 5 years, with a median of -$25000.0 in 2024.
- Annual changes were most pronounced in 2025 — Other Working Capital Changes slumped 178.16% — and 2026, when it increased 7.82%.
- Matinas BioPharma Holdings' Other Working Capital Changes stood at -$129000.0 in 2022, then retreated by 17.05% to -$151000.0 in 2023, then retreated by 15.23% to -$174000.0 in 2024, then plunged by 178.16% to -$484000.0 in 2025, then jumped by 65.91% to -$165000.0 in 2026.
- Business Quant data shows MTNB's Other Working Capital Changes at -$165000.0 in Q1 2026, -$484000.0 in Q4 2025, and -$195000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35,000.00 |
| Jun 30, 2026 | -35,000.00 |
| Jun 30, 2026 | -35,000.00 |
| Mar 31, 2026 | 341,000.00 |
| Mar 31, 2026 | 341,000.00 |
| Mar 31, 2026 | 341,000.00 |
| Dec 31, 2025 | -141,000.00 |
| Dec 31, 2025 | -141,000.00 |
| Dec 31, 2025 | -141,000.00 |
| Sep 30, 2025 | -205,000.00 |
| Sep 30, 2025 | -205,000.00 |
| Sep 30, 2025 | -205,000.00 |
| Jun 30, 2025 | -200,000.00 |
| Jun 30, 2025 | -200,000.00 |
| Jun 30, 2025 | -200,000.00 |
| Mar 31, 2025 | -119,000.00 |
| Mar 31, 2025 | -119,000.00 |
| Mar 31, 2025 | -119,000.00 |
| Dec 31, 2024 | 252,000.00 |
| Dec 31, 2024 | 252,000.00 |